CL2016001150A1 - Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas. - Google Patents

Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.

Info

Publication number
CL2016001150A1
CL2016001150A1 CL2016001150A CL2016001150A CL2016001150A1 CL 2016001150 A1 CL2016001150 A1 CL 2016001150A1 CL 2016001150 A CL2016001150 A CL 2016001150A CL 2016001150 A CL2016001150 A CL 2016001150A CL 2016001150 A1 CL2016001150 A1 CL 2016001150A1
Authority
CL
Chile
Prior art keywords
chlorophenyl
hydroxypyridin
carbonyl
compositions
acetic acid
Prior art date
Application number
CL2016001150A
Other languages
English (en)
Inventor
James Densmore Copp
Ann W Newman
Anne Luong
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of CL2016001150A1 publication Critical patent/CL2016001150A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPUESTO CRISTALINO DEL ACIDO {[5-(3-CLOROFENIL)-3-HlDROXIPlRIDIN-2-CARBONIL]AMlNO}ACETICO; METODO PARA PREPARARLO; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; FORMA DE DOSIFICIACION ORAL QUE LO COMPRENDE; Y METODO PARA TRATAR ANEMIA, TAL COMO LA ANEMIA PROVOCADA POR ENFERMEDAD RENAL CRONICA.
CL2016001150A 2013-11-15 2016-05-13 Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas. CL2016001150A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
CL2016001150A1 true CL2016001150A1 (es) 2016-12-09

Family

ID=53058045

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001150A CL2016001150A1 (es) 2013-11-15 2016-05-13 Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3068394A4 (es)
JP (4) JP2016537365A (es)
KR (2) KR102495018B1 (es)
CN (2) CN105916502A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20160222U (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX2021001169A (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (1) PH12016500866A1 (es)
RU (2) RU2021125455A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10202012791TA (es)
TW (4) TWI846166B (es)
WO (1) WO2015073779A1 (es)
ZA (2) ZA201603189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
NO2686520T3 (es) 2011-06-06 2018-03-17
CA2914662C (en) 2013-06-13 2022-05-31 Robert Shalwitz Compositions and methods for treating anemia
BR112016011065B1 (pt) 2013-11-15 2022-10-25 Akebia Therapeutics, Inc Composto cristalino e seu uso, composição farmacêutica e seu uso, forma de dosagem, método para preparar um composto
EP3096617A4 (en) * 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2016118858A1 (en) * 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
PE20180189A1 (es) 2015-04-01 2018-01-23 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de la anemia
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
ES2831863T3 (es) * 2016-12-13 2021-06-09 Crystal Pharmaceutical Suzhou Co Ltd Nuevas formas cristalinas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético y procesos de preparación de las mismas
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
EP3887356B1 (en) 2018-11-28 2023-08-02 Sandoz AG Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) * 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
US20230263786A1 (en) * 2020-06-19 2023-08-24 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
IL305487A (en) * 2021-03-01 2023-10-01 Akebia Therapeutics Inc Modulation of drug-drug interactions by VADADUSTAT

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
EP0381759A4 (en) 1988-07-25 1990-12-12 Vsesojuzny Kurgansky Nauchny Tsentr "Vosstanovitelnaya Travmatologia I Ortopedia" Traction apparatus for restoring the shape of the hand
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2000509047A (ja) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1999048870A1 (en) 1998-03-23 1999-09-30 Aventis Pharmaceuticals Products Inc. Piperididinyl and n-amidinopiperidinyl derivatives
SI20581B (sl) 1998-08-27 2008-06-30 Teva Pharma Nove hidratne oblike natrijevega alendronata, postopki za njihovo pridobivanje in ustrezne farmacevtske učinkovine
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
JP2002531427A (ja) 1998-11-27 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド セルトラリン塩酸塩多形体
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
WO2001010441A1 (en) 1999-08-11 2001-02-15 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
SI1235799T1 (en) 1999-11-17 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CZ20021998A3 (cs) 1999-12-14 2003-02-12 Biogal Gyogyszergyar Rt. Nové formy sodné soli pravastatinu
PL356243A1 (en) 1999-12-16 2004-06-28 Teva Pharmaceuticals Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
RU2002116232A (ru) 1999-12-16 2004-01-10 Тева Фамэситикл Индастрис Лтд. (Il) Способ получения полиморфных модификаций кларитромицина и новой полиморфной модификации IV
KR100791872B1 (ko) 1999-12-21 2008-01-07 테바 파마슈티컬 인더스트리즈 리미티드 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
EP1280535B1 (en) 2000-01-11 2005-02-09 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
DK1309547T3 (da) 2000-07-27 2007-05-21 Teva Pharma Krystallinsk og ren modafinil og fremgangsmåde til fremstilling af samme
CZ20031298A3 (cs) 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CN1498216A (zh) 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
IL155734A0 (en) 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002064557A2 (en) 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
AU2002305162A1 (en) 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
SK472004A3 (en) 2001-08-01 2004-12-01 Biogal Gyogyszergyar Purification and crystalline forms of zaleplon
CN1551880A (zh) 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
JP2005504818A (ja) 2001-10-03 2005-02-17 テバ ファーマシューティカル インダストリーズ リミティド レボフロキサシンおよびその形態の調製
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1453509A2 (en) 2001-11-08 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
CA2672549A1 (en) 2001-11-14 2003-06-12 Ben-Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
EP1463823B1 (en) 2001-12-06 2013-03-06 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
EP1467735B1 (en) 2001-12-18 2008-12-10 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
IL162457A0 (en) 2001-12-28 2005-11-20 Biogal Pharmaceutical Co Processes for preparing crystalline and amorphous mupirocin calcium
WO2003059807A2 (en) 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
DE03713610T1 (de) 2002-02-15 2005-10-20 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
WO2003080065A1 (en) 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2003082857A2 (en) 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
WO2003086355A1 (en) 2002-04-11 2003-10-23 Teva Pharmaceutical Indudstries, Ltd. Novel polymorphs and pseudopolymorphs of risedronate sodium
AU2003251290A1 (en) 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
JP2005529908A (ja) 2002-04-30 2005-10-06 テバ ジョジセルジャール レースベニュタールシャシャーグ オンダンセトロンの新規結晶形、その製法、当該新規形を含有する医薬組成物、及び当該組成物を用いる吐気の治療方法
EP1503762A2 (en) 2002-05-10 2005-02-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
AU2003248657A1 (en) 2002-06-10 2003-12-22 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
EP1471911A1 (en) 2002-06-14 2004-11-03 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004009532A1 (en) 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
EP1545530A1 (en) 2002-08-06 2005-06-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of gatifloxacin
AU2003268213A1 (en) 2002-08-26 2004-03-11 Teva Pharmaceutical Industries Ltd. Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
AU2003297594A1 (en) 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP2006511618A (ja) 2002-12-12 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの結晶形態および調製の方法
AU2003300324A1 (en) 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
ES2245277T1 (es) 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
US20040242619A1 (en) 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
ES2238022T3 (es) 2003-03-17 2008-11-01 Teva Pharmaceutical Industries Ltd. Poliformos de valsartan.
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
WO2005000850A2 (en) 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
CA2528192A1 (en) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd Cristalline ziprasidone hcl and processes for preparation thereof
BRPI0411055B1 (pt) 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CA2613021A1 (en) 2003-06-18 2004-12-29 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal form lxxx, processes for preparing, compositions and methods of using
DE602004019881D1 (de) 2003-07-03 2009-04-23 Teva Pharma Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7504504B2 (en) 2003-12-16 2009-03-17 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
US20050165085A1 (en) 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
US20050197347A1 (en) 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
EP1709002A2 (en) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
WO2005074935A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
EP1628959A2 (en) 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US20060004102A1 (en) 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
KR20080091298A (ko) 2004-05-18 2008-10-09 테바 파마슈티컬 인더스트리즈 리미티드 결정성 고체 팜시클로버의 제조를 위한 건조방법
US20050272821A1 (en) 2004-05-20 2005-12-08 Valeriano Merli Levalbuterol hydrochloride Polymorph A
MX2007000087A (es) 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
US20060142283A1 (en) 2004-06-29 2006-06-29 Judith Aronhime Crystalline form IV of linezolid
KR20070034080A (ko) 2004-07-01 2007-03-27 테바 파마슈티컬 인더스트리즈 리미티드 1,24(ｓ)-디히드록시 비타민 ｄ2의 결정형
CA2573781A1 (en) 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
JP2007505944A (ja) 2004-07-22 2007-03-15 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム及びその調製の方法
CN1976894A (zh) 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
PT1713489E (pt) 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
JP2007513889A (ja) 2004-09-21 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド 結晶性クロピドグレル臭酸塩及びその調製方法
JP2008514641A (ja) 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
CA2582092A1 (en) 2004-11-02 2006-05-11 Teva Pharmaceutical Industries Ltd. Tadalafil crystal forms and processes for preparing them
JP2008516001A (ja) 2004-11-03 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 非晶質、および多形のフォームのテルミサルタン・ナトリウム
US20060211751A1 (en) 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
US7439252B2 (en) 2004-12-01 2008-10-21 TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság Ascomycin crystalline forms and preparation thereof
JP2007526251A (ja) 2004-12-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド エゼチミベ多形体
PT1836157E (pt) 2005-01-11 2009-11-24 Teva Pharm Fine Chemicals Srl Polimorfos de cloridrato de memantina
EP1776049A2 (en) 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
US7335685B2 (en) 2005-02-24 2008-02-26 Teva Pharmaceutical Industries, Ltd. Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US7291614B2 (en) 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
EP1856087A1 (en) 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
US20060270684A1 (en) 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
WO2006108151A1 (en) 2005-04-06 2006-10-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
MX349340B (es) 2005-05-23 2017-07-24 Intercontinental Great Brands Llc Composiciones potenciadoras del sabor y bebidas que contienen las mismas.
MX2007000983A (es) 2005-05-23 2007-04-16 Teva Pharma Procesos para preparar la forma cristalina i de clorhidrato de cinacalcet.
CA2610956A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
EP1781611A1 (en) 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
WO2007008317A2 (en) 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
JP2008514734A (ja) 2005-06-22 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド マレイン酸テガセロドの多型体
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
EP1828208A2 (en) 2005-10-31 2007-09-05 Teva Pharmaceutical Industries Ltd Crystalline form of cefdinir cesium salt
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
KR20080055990A (ko) 2005-11-22 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1861397A2 (en) 2006-01-05 2007-12-05 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Production of dolasetron
BRPI0706377A2 (pt) 2006-01-09 2011-03-22 Btg Int Ltd moduladores de fator -1 induzìvel por hipoxia e usos relacionados
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US20070225507A1 (en) 2006-01-18 2007-09-27 Gustavo Frenkel Process for preparing a crystalline form of Tegaserod maleate
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
JP2009508880A (ja) 2006-02-21 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アルモダフィニルの新規な結晶形とその調製方法
ES2300236T1 (es) 2006-02-27 2008-06-16 Teva Pharmaceutical Industries Ltd Formas novedosas de fluvastatina sodica y su preparacion.
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
WO2007109799A2 (en) 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
AU2008248234B2 (en) 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101918444A (zh) 2007-11-08 2010-12-15 健泰科生物技术公司 抗因子b抗体及其用途
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
CN101983384A (zh) 2007-11-30 2011-03-02 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
EP2224926A4 (en) 2007-11-30 2010-12-01 Glaxosmithkline Llc INHIBITORS OF PROLYL HYDROXYLASES
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
NO2686520T3 (es) 2011-06-06 2018-03-17
AU2012289429B2 (en) 2011-07-22 2016-07-28 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
CA2914662C (en) 2013-06-13 2022-05-31 Robert Shalwitz Compositions and methods for treating anemia
BR112016011065B1 (pt) 2013-11-15 2022-10-25 Akebia Therapeutics, Inc Composto cristalino e seu uso, composição farmacêutica e seu uso, forma de dosagem, método para preparar um composto
EP3096617A4 (en) 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CA2979985A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
PE20180189A1 (es) 2015-04-01 2018-01-23 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de la anemia
ES2831863T3 (es) 2016-12-13 2021-06-09 Crystal Pharmaceutical Suzhou Co Ltd Nuevas formas cristalinas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético y procesos de preparación de las mismas
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
WO2021087144A1 (en) 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
JP2019167353A (ja) 2019-10-03
US9701636B2 (en) 2017-07-11
EP3578546A1 (en) 2019-12-11
SA516371129B1 (ar) 2019-07-28
TW201946625A (zh) 2019-12-16
ZA201603189B (en) 2019-11-27
AR099354A1 (es) 2016-07-20
JP2022176961A (ja) 2022-11-30
BR112016011065A8 (pt) 2020-04-22
AU2019202144A1 (en) 2019-04-18
AU2020294308A1 (en) 2021-02-18
US20220040159A1 (en) 2022-02-10
BR112016011065A2 (pt) 2017-08-08
SG10201803862UA (en) 2018-06-28
MX2021001169A (es) 2023-02-10
AR128483A2 (es) 2024-05-15
KR20220042498A (ko) 2022-04-05
TWI788702B (zh) 2023-01-01
CN114890943A (zh) 2022-08-12
TW201605801A (zh) 2016-02-16
JP2020183408A (ja) 2020-11-12
EP3068394A4 (en) 2017-04-26
US20180280365A1 (en) 2018-10-04
US20190290624A1 (en) 2019-09-26
WO2015073779A1 (en) 2015-05-21
TWI665190B (zh) 2019-07-11
CR20160222U (es) 2016-08-26
US9987262B2 (en) 2018-06-05
TW202335670A (zh) 2023-09-16
BR112016011065B1 (pt) 2022-10-25
RU2016123382A (ru) 2017-12-20
DOP2016000109A (es) 2016-08-31
MX2021007268A (es) 2021-07-15
US10149842B2 (en) 2018-12-11
EP3068394A1 (en) 2016-09-21
RU2021125455A (ru) 2021-10-05
TWI846166B (zh) 2024-06-21
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
KR20160083118A (ko) 2016-07-11
US20200345711A1 (en) 2020-11-05
NZ759132A (en) 2022-03-25
US10596158B2 (en) 2020-03-24
CR20200220A (es) 2020-11-18
MA39033A1 (fr) 2017-11-30
PH12016500866A1 (en) 2016-06-20
IL281648A (en) 2021-05-31
IL245634A0 (en) 2016-06-30
US20170258773A1 (en) 2017-09-14
CA2930128A1 (en) 2015-05-21
ZA201905255B (en) 2020-11-25
AU2014348523B2 (en) 2019-01-03
SG10202012791TA (en) 2021-01-28
AU2022259767B2 (en) 2024-08-15
AU2014348523A1 (en) 2016-06-09
US11690836B2 (en) 2023-07-04
MX2016006271A (es) 2017-05-04
PE20160945A1 (es) 2016-09-26
US11065237B2 (en) 2021-07-20
KR102495018B1 (ko) 2023-02-06
JP2016537365A (ja) 2016-12-01
CN105916502A (zh) 2016-08-31
AU2020294308B2 (en) 2022-08-11
US20240122910A1 (en) 2024-04-18
US20150141467A1 (en) 2015-05-21
AU2019202144B2 (en) 2020-10-08
AU2022259767A1 (en) 2022-12-01
MY180626A (en) 2020-12-03
TW202126300A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
CL2016001150A1 (es) Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2016000253A (es) Nuevos compuestos
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DK3068392T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PH12016500094A1 (en) Autotaxin inhibitors
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
CL2015003346A1 (es) Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
GT201500247A (es) Imidazopiridazinas sustituidas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
EA201600434A1 (ru) Применение производных бензимидазолпролина
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.